Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

1306 details
Primary information
ThPP IDTh1043
Therapeutic Peptide/Protein NameRasburicase
SequenceSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKAD view full sequnce in fasta
Functional ClassificationIc
Molecular Weight34109.5
Chemical FormulaC1521H2381N417O461S7
Isoelectric Point7.16
Hydrophobicity-0.465
Melting Point (℃)N.A.
Half Life18 hours
DescriptionRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae< strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Indication/DiseaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy).
PharmacodynamicsDrugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Mechanism of ActionRasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution75.8 to 138 mL/kg [adult patients]
ClearanceN.A.
CategoriesAntihyperuricemic Agents
Patents NumberCA2148537
Date of Issue16/07/02
Date of Expiry03/05/15
Drug InteractionCitanest Forte (epinephrine / prilocaine)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearnceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationIndividulas deficient in glucose -6-phosphate dehydrogenase.
Side EffectsN.A.
Useful Linkhttp://www.drugs.com/cdi/elitek.html
PubMed ID20445229, 20394650
3-D StructureTh1043 (View) or (Download)